BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Cancer

  ESMO 2026: Analysts warm to Merck, Moderna’s cancer vaccine after frustrating data leak

  After sitting through the full presentation on the Phase 3 INTerpath-001 trial at the ESMO Congress over the weekend, analysts are more keen on the personalized mRNA cancer vaccine data that last week spurred a stock selloff for both partners.

  October 26, 2026

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  Cancer

  ESMO 2026: Merck’s Kelun-partnered ADC cuts death risk by over 30% in endometrial cancer

  Sac-TMT significantly extended overall and progression-free survival for patients with advanced or recurrent endometrial cancer by 6.9 months over chemotherapy in a Phase 3 trial—becoming the first TROP2-directed ADC to do so in this setting, Merck told BioSpace.

  October 26, 2026

   · 

  4 min read

   · 

  Heather McKenzie
• 

  Prostate cancer

  ESMO 2026: J&J delivers ‘immaculate’ early data for prostate cancer drug from Halda

  JNJ-6143, which came from Johnson & Johnson’s $3 billion takeover of Halda Therapeutics in 2025, showed a 75% overall response rate in the Phase 1 readout.

  October 26, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  CasZyme and Cirena to Collaborate on Developing Longer Guide RNAs to Optimise Cas12l Performance

  October 26, 2026

   · 

  2 min read
• Press Releases

  Dragonfleye Therapeutics Corp. Takes Flight, Raising US$37.5 Million in Private Placement Offerings to Advance Novel Ocular Platform-Based Treatments

  October 26, 2026

   · 

  3 min read
• Press Releases

  Riboscience Presents Phase 1a/b Overall Survival Data for ENPP1 Inhibitor RBS2418 as Monotherapy and in Combination Therapy in Advanced Solid Tumors and Late-Line CRC

  October 26, 2026

   · 

  6 min read
• Press Releases

  Therma Bright Announces up to $420,000 Non-Brokered Private Placement

  October 26, 2026

   · 

  4 min read
• Press Releases

  Chidamide Plus Nivolumab Shows Potential as New Standard of Care in Advanced Melanoma, Reducing Disease Progression Risk by 27% in Global Phase 3 Trial

  October 26, 2026

   · 

  5 min read
• Press Releases

  MustGrow Announces “Fireside Chat” Webcast with Bayer AG

  October 26, 2026

   · 

  3 min read
• Press Releases

  Theralase Provides Bladder Cancer Clinical Study Update

  October 26, 2026

   · 

  7 min read